Yin Xiaolu, Zhang Tianwei, Su Xinying, Ji Yan, Ye Peng, Fu Haihua, Fan Shuqiong, Shen Yanying, Gavine Paul R, Gu Yi
Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
Research & Development Information, AstraZeneca R&D, Shanghai, China.
PLoS One. 2015 Dec 4;10(12):e0143468. doi: 10.1371/journal.pone.0143468. eCollection 2015.
To investigate the relationships between Chromosome 7 gain, mesenchymal-epithelial transition factor (MET) gene copy number increase and MET protein overexpression in Chinese patients with papillary renal cell carcinoma (PRCC), immunohistochemistry (IHC), immunofluorescence (IF) and fluorescence in situ hybridization (FISH) were performed on 98 formalin-fixed, paraffin-embedded (FFPE) PRCC samples. Correlations between MET gene copy number increase, Chromosome 7 gain and MET protein overexpression were analyzed statistically. A highly significant correlation was observed between the percentage of tumor cells with MET gene copy number ≥3 and CEP7 copy number ≥3 (R2 = 0.90, p<0.001) across two subtypes of PRCC. In addition, the percentage of tumor cells with MET gene copy number ≥3 was found to increase along with increases in MET IHC score. This correlation was further confirmed in those PRCC tumor cells with average MET gene copy number >5 using combined IF and FISH methodology. Overall, this study provides evidence that Chromosome 7 gain drives MET gene copy number increase in PRCC tumors, and appears to subsequently lead to an increase in MET protein overexpression in these tumor cells. This supports MET activation as a potential therapeutic target in sporadic PRCC.
为了研究中国乳头状肾细胞癌(PRCC)患者中7号染色体增加、间充质-上皮转化因子(MET)基因拷贝数增加与MET蛋白过表达之间的关系,对98例福尔马林固定、石蜡包埋(FFPE)的PRCC样本进行了免疫组织化学(IHC)、免疫荧光(IF)和荧光原位杂交(FISH)检测。对MET基因拷贝数增加、7号染色体增加和MET蛋白过表达之间的相关性进行了统计学分析。在PRCC的两种亚型中,观察到MET基因拷贝数≥3的肿瘤细胞百分比与CEP7拷贝数≥3之间存在高度显著相关性(R2 = 0.90,p<0.001)。此外,发现MET基因拷贝数≥3的肿瘤细胞百分比随MET IHC评分的增加而增加。使用联合IF和FISH方法在平均MET基因拷贝数>5的PRCC肿瘤细胞中进一步证实了这种相关性。总体而言,本研究提供了证据表明7号染色体增加驱动PRCC肿瘤中MET基因拷贝数增加,并且似乎随后导致这些肿瘤细胞中MET蛋白过表达增加。这支持MET激活作为散发性PRCC的潜在治疗靶点。